Anal adenocarcinoma: a rare malignancy in need of multidisciplinary management

Jelena Lukovic; John J. Kim; Monika Krzyzanowska; Sami A. Chadi; Cullen M. Taniguchi; Ali Hosni

doi:10.1200/OP.20.00363

Anal adenocarcinoma: a rare malignancy in need of multidisciplinary management

Jelena Lukovic, John J. Kim, Monika Krzyzanowska, Sami A. Chadi, Cullen M. Taniguchi, Ali Hosni

Radiation Oncology

Research output: Contribution to journal › Review article › peer-review

12 Scopus citations

Abstract

Adenocarcinoma of the anal canal is an uncommon malignancy, making it challenging to perform randomized controlled clinical trials to define best practices in care. For patients with localized disease, there remains a lack of consensus regarding the optimal management, with some physicians advocating for trimodality therapy (similar to the locally advanced rectal adenocarcinoma paradigm) and others advocating for definitive radiation therapy with concurrent chemotherapy (similar to the management of anal squamous cell carcinoma). The objective of this clinical review is to describe the management and outcomes of patients with anal adenocarcinoma to help inform treatment recommendations.

Original language	English (US)
Pages (from-to)	635-640
Number of pages	6
Journal	JCO Oncology Practice
Volume	16
Issue number	10
DOIs	https://doi.org/10.1200/OP.20.00363
State	Published - Oct 1 2020

ASJC Scopus subject areas

Oncology
Health Policy
Oncology(nursing)

Access to Document

10.1200/OP.20.00363

Cite this

@article{b34a77de37344d579d10bb39d7f141a4,

title = "Anal adenocarcinoma: a rare malignancy in need of multidisciplinary management",

abstract = "Adenocarcinoma of the anal canal is an uncommon malignancy, making it challenging to perform randomized controlled clinical trials to define best practices in care. For patients with localized disease, there remains a lack of consensus regarding the optimal management, with some physicians advocating for trimodality therapy (similar to the locally advanced rectal adenocarcinoma paradigm) and others advocating for definitive radiation therapy with concurrent chemotherapy (similar to the management of anal squamous cell carcinoma). The objective of this clinical review is to describe the management and outcomes of patients with anal adenocarcinoma to help inform treatment recommendations.",

author = "Jelena Lukovic and Kim, {John J.} and Monika Krzyzanowska and Chadi, {Sami A.} and Taniguchi, {Cullen M.} and Ali Hosni",

note = "Publisher Copyright: . {\textcopyright} 2020 by American Society of Clinical Oncology",

year = "2020",

month = oct,

day = "1",

doi = "10.1200/OP.20.00363",

language = "English (US)",

volume = "16",

pages = "635--640",

journal = "JCO Oncology Practice",

issn = "2688-1527",

publisher = "American Society of Clinical Oncology",

number = "10",

}

TY - JOUR

T1 - Anal adenocarcinoma

T2 - a rare malignancy in need of multidisciplinary management

AU - Lukovic, Jelena

AU - Kim, John J.

AU - Krzyzanowska, Monika

AU - Chadi, Sami A.

AU - Taniguchi, Cullen M.

AU - Hosni, Ali

PY - 2020/10/1

Y1 - 2020/10/1

N2 - Adenocarcinoma of the anal canal is an uncommon malignancy, making it challenging to perform randomized controlled clinical trials to define best practices in care. For patients with localized disease, there remains a lack of consensus regarding the optimal management, with some physicians advocating for trimodality therapy (similar to the locally advanced rectal adenocarcinoma paradigm) and others advocating for definitive radiation therapy with concurrent chemotherapy (similar to the management of anal squamous cell carcinoma). The objective of this clinical review is to describe the management and outcomes of patients with anal adenocarcinoma to help inform treatment recommendations.

AB - Adenocarcinoma of the anal canal is an uncommon malignancy, making it challenging to perform randomized controlled clinical trials to define best practices in care. For patients with localized disease, there remains a lack of consensus regarding the optimal management, with some physicians advocating for trimodality therapy (similar to the locally advanced rectal adenocarcinoma paradigm) and others advocating for definitive radiation therapy with concurrent chemotherapy (similar to the management of anal squamous cell carcinoma). The objective of this clinical review is to describe the management and outcomes of patients with anal adenocarcinoma to help inform treatment recommendations.

UR - http://www.scopus.com/inward/record.url?scp=85092885658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85092885658&partnerID=8YFLogxK

U2 - 10.1200/OP.20.00363

DO - 10.1200/OP.20.00363

M3 - Review article

C2 - 33049179

AN - SCOPUS:85092885658

SN - 2688-1527

VL - 16

SP - 635

EP - 640

JO - JCO Oncology Practice

JF - JCO Oncology Practice

IS - 10

ER -

Anal adenocarcinoma: a rare malignancy in need of multidisciplinary management

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this